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Abstract
OBJECTIVES: The increasing relevance of the cancer stem cell (CSC) hypothesis and the impact of CSC-associated markers in the car-
cinogenesis of solid tumours may provide potential prognostic implications in lung cancer. We propose that a collective genetic analysis
of established CSC-related markers will generate data to better deﬁne the role of putative CSCs in lung adenocarcinoma (LAC).
METHODS: Sixty-four paired tumour and non-tumour biopsies from LAC patients were included in this study. Using the quantitative
reverse transcriptase–polymerase chain reaction, we assessed the expression proﬁles of established CSC-related biomarkers: octamer-
binding transcription factor 4 (OCT4A), CD133, aldehyde dehydrogenase (ALDH), BMI-1, ATP-binding cassette subfamily G, member 2
(ABCG2), SRY (sex-determining region Y)-box 2 (SOX2) and uPAR, and evaluated their relation to clinicopathological parameters and
disease prognosis.
RESULTS: All of the above-mentioned CSC-related markers were detectable in both tumour and corresponding normal tissues.
Importantly, expression levels of OCT4A, CD133, BMI-1, SOX2 and uPAR were signiﬁcantly higher (OCT4A, P = 0.0003; CD133,
P = 0.002; BMI-1, P = 0.04; SOX2, P = 0.0003; uPAR, P = 0.03) in the tumour compared with those in the non-tumour tissues. By contrast,
the quantities of ACBG2 and ALDH were markedly reduced (ACBG2, P = 0.0006; ALDH, P = 0.007) in the tumour relative to those in the
normal biopsies. Using multivariate analysis, elevated ALDH and CD133 revealed signiﬁcant associations in tumour stage (ALDH,
P = 0.03; CD133, P = 0.007) and differentiation (ALDH, P = 0.03; CD133, P = 0.018). We observed that ALDH and OCT4A were associated
with nodal status (ALDH, P = 0.05; OCT4A, P = 0.03) having lower mRNA levels in tumours with lymph node metastasis, N+, compared
with that in N0. High OCT4A levels were signiﬁcantly correlated with tumour size of <3 cm, decrease in tumours >3 cm (P = 0.03).
Kaplan–Meier correlation analyses, showed that OCT4A and CD133 were correlated to short disease-free intervals (OCT4A, P = 0.047;
CD133, P = 0.033) over a period of 29 months.
CONCLUSIONS: Our study reveals that CSC-associated markers: OCT4A, CD133 and ALDH are involved in the initial phase of carcino-
genesis of LAC, and can be used as predictors of early stage LAC and poor disease-free intervals. In addition, this work validates the
relevance of the CSC hypothesis in LAC.
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INTRODUCTION
Lung cancer is one of the major causes of cancer-related
death worldwide. Adenocarcinoma, the most common form of
non-small cell lung cancer (NSCLC), is the most prevalent,
representing 40% of the NSCLC cases, with an increasing
incidence and <15% of patients with an overall 5-year survival [1].
Hence, further exploration of the factors surrounding the onco-
genesis of this tumour may reveal novel approaches to improve
the efﬁcacy of treatment and assure a better clinical outcome.
The cancer stem cell (CSC) model is a conceivable explanation
for the oncogenesis of lung adenocarcinoma (LAC). The hall-
marks of CSCs to self-renew and undergo asymmetric divisions
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producing differentiated progeny enable CSCs to initiate as well
as promote cancer progression. An increasing number of studies
have underscored the relevance of the expression proﬁles of
CSC-associated markers and/or embryonic stem cell genes in re-
lation to cancer initiation, progression and clinical prognosis,
thus presenting these as prognostic tools in predicting patient
survival. Established CSC indicators in lung cancer include alde-
hyde dehydrogenase (ALDH), prominin-1 (CD133), ATP-binding
cassette subfamily G, member 2 (ABCG2), octamer-binding tran-
scription factor 4 (OCT4A) and SRY (sex-determining region
Y)-box 2 (SOX2). Urokinase plasminogen activator receptor
(uPAR) and polycomb ring ﬁnger oncogene (BMI-1) have also
been linked to lung tumorigenesis.
ALDH is a detoxifying enzyme, sought to protect organisms
against various aldehydes that would otherwise cause damage
and has been shown to play an oncogenic role in mammary,
prostate, ovarian and lung cancers [2]. OCT4A, a transcription
factor essential for maintaining pluripotency in embryonic stem
cells, has been proposed to have an essential role in the tumori-
genesis of solid tumours including those of bladder, gastric and
prostate [3]. Moreover, the presence of OCT4A, Nanog and slug
have been found in high-grade LAC tumours and marked a poor
prognosis for patients [4]. CD133 is a ﬁve-transmembrane glyco-
protein used to identify both normal and CSCs in different
tissues. Increased expression of CD133 has proved to be a useful
factor for prediction of correlation to prognosis, recurrence and
chemosensitivity in colorectal cancer [5]. Additionally, it has
been associated with lower survival resulting in poor prognosis
in gastric carcinoma, pancreatic cancer and glioma [6]. Its impli-
cations in tumorigenicity and chemoresistance in lung cancer
have been conﬁrmed by Bertolini et al. [7].
A number of studies have demonstrated the expression of and
associations among BMI-1, uPAR, SOX2, ABCG2 in the initiation,
maintenance and prognosis of speciﬁc neoplastic tissues. BMI-1
is a component of the polycomb repressive complex 1, a key epi-
genetic factor, which also controls the cell cycle and self-renewal
of tissue stem cells. Overexpression of BMI-1 is found to correlate
with poor prognosis in non-keratinizing types of nasopharyngeal
carcinoma, breast or hepatocellular carcinoma, as well as in the
nervous system [8]. SOX2 is a transcription factor essential for
early mammalian development and for the sustainment of
embryonic and adult stem cells. Overexpression of SOX2 has
been observed in different types of solid tumours including the
lung [9], thereby manifesting an oncogenic role. uPAR is the
cellular receptor for urokinase-type plasminogen activator, which
activates plasminogen into plasmin, and has been a target in
cancer research due to a role in both the progression of malig-
nant cancers and as a prognostic tool for poor patient survival
[10]. ABCG2, expressed in both normal and cancer cells, plays a
pivotal role in side population cells and efﬂux of xenobiotics and
drugs [11]. In the lung, a dual positive expression of CD133 and
ABCG2 has been shown to be an independent predictor of post-
operative recurrence for patients with stage 1 NSCLC [11].
Considering the inﬂuence of CSC-associated markers in evalu-
ating disease outcome and patient survival, we reasoned that
assessing the mRNA expression of these markers collectively
would generate data to support a plausible role of
CSC-associated biomarkers in the tumorigenesis of LAC. In this
study, we determined the mRNA levels of ALDH, CD133,
ABCG2, OCT4A, SOX2, BMI-1 and uPAR on resected paired
normal and tumour LAC tissues. Their expression proﬁles were
correlated to the TNM staging and clinicopathological features
of this disease. Our results reveal that only the presence of
ALDH, CD133 and OCT4A have a signiﬁcant clinical impact
on the initiation rather than progression and/or maintenance of
this neoplasm. These markers may serve as possible predictive
factors in early stage LAC manifesting signiﬁcantly shorter
disease-free intervals. To the best of our knowledge, this is the
ﬁrst study to examine LAC tumour and non-tumour tissues with
respect to CSC-marker expression proﬁles and their relevance to
the clinicopathological parameters of this disease.
MATERIALS AND METHODS
Sample collection
Normal and matched malignant biopsies of LAC were obtained
from 64 consenting patients undergoing tumour resection from
January 2008 to January 2011 at the European Institute of
Oncology in Milan, Italy. Diagnosis was based on clinical and
histological parameters. LAC tumour staging (pTNM) was classi-
ﬁed according to the current International Staging System. All
patients included in the study were subjected to primary surgery.
Patient age ranged from 34 to 86; 53% were male and 47%
female. None of the patients had undergone chemotherapy or
radiotherapy prior to surgery. Paired tumour and non-tumour
lung tissues were obtained by surgical resection. Tumour tissue
was resected from the periphery of the tumour, whereas normal
specimens were sampled at least 6 cm away from the tumour and
were conﬁrmed as non-malignant by pathological examination.
All biopsies (5 × 5 mm2) were immediately stored in RNAlater
solution (Qiagen; Hombrechtikon, Switzerland) and stored at −20°
C. The study was approved by both the medical ethical commit-
tees of University Hospital Berne (Berne, Switzerland) and the
European Institute of Oncology (Milan, Italy).
RNA extraction and quantitative real-time reverse
transcriptase–polymerase chain reaction
Tissue biopsies, preserved in RNAlater (Qiagen) were processed
by total RNA extraction (RNeasy Kit, Qiagen) according to the
manufacturer’s instructions. Complementary DNA (cDNA) was
synthesized using the High Capacity cDNA Reverse Transcription
kit (Applied Biosystems; Rotkreuz, Switzerland) and treated with
RNase-Free DNase (Qiagen). The mRNA transcript levels of the
housekeeping gene β2-Microglobulin, β2M, and target genes
OCT4A, CD133, BMI-1, SOX2, uPAR, ALDH1A1 (ALDH) and
ABCG2 were evaluated with commercially available TaqMan®
‘Assay on Demand’ primer/probes (β2M, Hs00984230_m1;
OCT4A, Hs03005111_g1; CD133, Hs01009254_m1; BMI-1,
Hs00180411_m1; SOX2, Hs01053049_s1; uPAR, Hs00182181_m1;
ALDH1A1, Hs00964880_m1 and ABCG2, Hs01055362_m1)
(Applied Biosystems; Rotkreuz). Twenty-ﬁve nanograms of result-
ing cDNAs were subjected to quantitative reverse transcriptase–
polymerase chain reaction (qRT–PCR) in a 12.5 μl ﬁnal reaction
volume and analysed in triplicate. Gene expression was detected
using ABI 7900 sequence detection system. All target gene Ct
values in each parameter were normalized by the reference gene,
β2M. The baseline and the threshold for Ct calculation were set
automatically with the ABI Prism SDS 2.1 software. The qRT–PCR
data represent the relative quantity of the target gene mRNA
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(target gene mRNA/β2M mRNA ratio) in comparison with the
human embryonic carcinoma cell line NTERA-2, which was used
as a calibrator and set at 1.
Statistical analysis
To assess the statistical signiﬁcance of differences observed in the
mRNA expression levels in tumour specimens and normal coun-
terparts, the Wilcoxon rank-sum, two-tailed test was performed.
Correlation between mRNA expression and the clinicopathological
parameters of tumour stage, and tumour grade were analysed by
an analysis of variance, speciﬁcally the Kruskal–Wallis test, followed
by the Dunn’s post hoc method. Patient age was dichotomized to
65 years of age or under and above 65 years. Similarly, nodal
status was dichotomized to nodal involvement and no nodal in-
volvement. For associations between the continuous variable
(gene expression) and dichotomous variables (patient sex, age
and nodal status), the Mann–Whitney U, non-parametric, two-
tailed test was performed. Spearman’s rank correlation coefﬁcients
(r) were calculated to estimate the correlation between expression
levels of different genes studied. Kaplan–Meier survival analysis
and the log-rank signiﬁcance test were utilized to analyse univari-
ate distributions for disease-free interval. Furthermore, a multivari-
ate analysis was done by using Cox proportional hazards
regression to determine the prognostic effect of OCT4A, CD133
and ALDH expression on disease-free interval. Hazard ratios and
their corresponding 95% conﬁdence intervals were computed to
provide quantitative information about the relevance of results of
the statistical analysis. P-values <0.05 were deﬁned as statistically
signiﬁcant (*). All statistical data were obtained using the GraphPad
Prism version 5.03 (GraphPad Software Inc., La Jolla, USA).
RESULTS
Patient demographics
Sixty-four patients with LAC were included in the study. The
patients consisted of 34 men and 30 women. The median age
was 62, 38 (59%) aged over 65 years. The histologic classiﬁcation
of the tumour was based on the World Health Organization
Figure 1: qRT–PCR mRNA analyses showing the relative mRNA levels in paired tumour and non-cancerous lung tissue. (a) OCT4A; (b) CD133; (c) ALDH; (d) BMI-1;
(e) ABCG2; (f ) SOX2; (g) uPAR. Messenger RNA levels were measured using the ΔΔCt method, relative to the calibrator, NTERA-2, an embryonic carcionoma cell
line.
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criteria. Thirty-eight (59%) had stage I disease, 14 patients (22%)
stage II disease and 12 patients (19%) had stage III disease. Of
the 64 patients, 23 (36%) had tumours with nodal metastasis and
the majority, 43 (67%) had a tumour size of <3 cm. The grade of
the tumours was equally distributed with 18 (28%) G1, 24
(37.5%) G2 and 22 (34%) G3. Sixty-eight per cent of the cases
had mixed subtype histology. Acinar pattern was the predomin-
ant subtype (34%), followed by papillary (23%), solid (22%) and
bronchioloalveolar (20%). Of the cases that contained a single
histologic subtype, 12 (60%) were acinar, 6 (30%) were bronchio-
loalveolar and 5 (25%) were solid.
Cancer stem cell-associated mRNA expression
levels in paired normal and tumour biopsies
One of the main objectives of our study was to determine if
there was a difference in the frequency of CSC-associated mRNA
levels between paired tumour and non-tumour tissues. qRT–PCR
analyses showed that CSC-associated biomarkers OCT4A, CD133,
BMI-1, SOX2, uPAR, ALDH and ABCG2 were detectable in the
majority of the paired tumour and normal LAC tissues. Sixty-one
of 64 pairs (95%) and 60/64 (94%) showed OCT4A and SOX2 ex-
pression with considerably higher OCT4A (P = 0.0003) and SOX2
(P = 0.0003) levels in the malignant tissues (Fig. 1a and f ). CD133
(Fig. 1b), BMI-1 (Fig. 1d), uPAR (Fig. 1g) signals were found in
63/64 (98%), 62/64 (97%) and 64/64 (100%) of the sample pairs,
respectively, likewise, with signiﬁcantly higher levels in the
tumour tissues (CD133, P = 0.002; BMI-1, P = 0.04; uPAR, P =
0.03). ALDH and ABCG2 expression were also detectable in 60/
64 (94%) and 55/64 (86%) of the pairs (Fig. 1c and e) but in con-
trast to the above-mentioned genes, the mRNA signals in the
tumour tissues were noticeably lower for both markers (ALDH,
P = 0.0006; ABCG2, P = 0.007). As cigarette smoke has been cor-
related to increased expression of ALDH, we evaluated whether
the high expression of this maker in the normal tissues could be
partly attributed to smoking. A comparative expression proﬁle of
the cohorts of smokers and non-smokers in normal tissues, illu-
strated a signiﬁcantly higher ALDH expression in the smoker
group (Fig. 2a). Removal of the smoking cohort resulted in sig-
niﬁcantly elevated levels of ALDH mRNA in tumour tissue biop-
sies compared with corresponding normal tissues (Fig. 2b).
Associations between cancer stem cell-associated
genes and clinicopathological parameters
To explore the relevance of the CSC-associated genes to clinico-
pathological parameters, correlation studies were performed.
Associations between the clinicopathological features of the 64
patients with LAC and putative CSC biomarkers are shown in
Table 1. There were no obvious interdependencies between any of
the genes evaluated: OCT4A, CD133, BMI-1, SOX2, uPAR, ALDH and
ABCG2 and age or gender of the patients. In addition, no substantial
correlation of SOX2, uPAR and ABCG2, to tumour stage, nodal
status, tumour size, grade and histological subtype was observed,
except for BMI-1, which showed an association with tumour size.
Evaluation by the Kruskal–Wallis test, an analysis of variance,
revealed marked associations of ALDH and CD133 with both
tumour stage as well as differentiation (Fig. 3a, b, d and e).
Elevated ALDH and CD133 mRNA signals were observed in the
early phases of tumour stage (ALDH, P = 0.02; CD133, P = 0.007)
and differentiation (ALDH, P = 0.03; CD133, P = 0.02) which
declined upon progression of these parameters. Importantly,
higher mRNA levels of these genes were found in poorly differ-
entiated tumours (CD133: G1 vs. G3, P = 0.02; ALDH: G1 vs. G3,
P = 0.03) as well as in stage I tumours (CD133: stage I vs. stage
III, P = 0.006; ALDH: stage I vs. stage III, P = 0.08). We also
observed that ALDH and OCT4A were signiﬁcantly related to
nodal status (Fig. 2c and g) with lower mRNA levels in patients
with lymph node metastasis, N+ compared with that in N0.
Increased OCT4A occurrence correlated to tumour size of <3 cm,
which was markedly lower in tumours of >3 cm (Fig. 3f ).
Given the previously reported evidence of interdependency of
CSC markers, we explored this relationship between OCT4A,
CD133 and ALDH. Spearman correlation coefﬁcients were calcu-
lated to determine a potential correlation of OCT4A, CD133 and
ALDH (Fig. 4). The results revealed that the degree of expression
levels of OCT4A were positively related with those of CD133 (r =
0.4; P = 0.002). No correlation was observed between OCT4A
and ALDH or CD133 and ALDH.
Cancer stem cell-associated gene expression in
relation to disease-free progression and survival
The median disease-free interval and median survival time for
the patients were 13 months (range, 1–29 months) and 16.5
months (range, 7–29 months), respectively. A cut-off value was
deﬁned by taking the median value for the gene transcript levels
of OCT4A, CD133 and ALDH. Values higher than the median
were considered as high expression; and values below the
median were regarded as low expression. Univariate analysis
(log-rank test) of the effect prognostic parameters on disease-
free interval depicted that OCT4A (P = 0.047) and CD133 (P =
0.033) expression levels were independent prognostic factors of
disease-free interval (Table 2). Patients with low expression of
OCT4A and CD133 had markedly longer disease-free intervals
Figure 2: qRT–PCR mRNA analyses showing the relative ALDH mRNA levels
in (a) normal lung tissue from ‘smokers’ in comparison with ‘non-smokers’
and (b) paired tumour and non-cancerous lung tissue of the ‘non-smoking’
cohort. Messenger RNA levels were measured using the ΔΔCt method, rela-
tive to the calibrator, NTERA-2, an embryonic carcionoma cell line.
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Table 1: Clinicopathological variables and the corresponding expression of CSC-associated genes
Variables Total OCT4A P-value CD133 P-value BMI-1 P-value SOX2 P-value uPAR P-value ALDH P-value ABCG2 P-value
−(n) +(n) −(n) +(n) −(n) +(n) −(n) +(n) −(n) +(n) −(n) +(n) −(n) +(n)
Total 64 3 61 1 63 2 62 4 60 0 64 1 60 9 55
Age
>65 38 2 36 0.72 1 37 0.81 1 37 0.76 3 35 0.68 0 38 0.82 3 35 0.97 4 34 0.88
<65 26 1 25 0 26 1 25 1 25 0 26 1 25 5 21
Gender
Male 34 2 32 0.91 1 33 0.65 2 32 0.83 3 31 0.73 0 34 0.71 2 32 0.59 5 29 0.92
Female 30 1 29 0 30 0 30 1 29 0 30 2 28 4 26
Smoking
Yes 33 2 31 0.65 1 32 0.58 1 32 0.87 1 32 0.79 0 33 0.28 2 31 0.33 6 28 0.16
No 31 1 30 0 31 1 30 3 28 0 31 2 29 3 27
Pathological stage
I 38 1 37 0.95 0 38 0.007 1 37 0.96 4 34 0.49 0 38 0.26 2 36 0.03 5 33 0.64
II 14 1 13 0 14 1 13 0 14 0 14 0 14 1 13
III 12 0 12 1 11 0 12 0 12 0 12 2 10 3 9
Nodal status
N0 23 1 22 0.25 0 23 0.37 1 22 0.26 3 20 0.98 0 23 0.08 2 21 0.047 5 18 0.85
N+ 41 2 39 1 40 1 40 1 40 0 41 2 39 4 37
Tumour size
≤3 cm 43 1 42 0.027 1 42 0.28 1 42 0.002 4 39 0.14 0 43 0.53 0 43 0.21 3 40 0.81
>3 cm 21 2 19 0 21 1 20 0 21 0 21 3 18 6 15
Tumour grade
G1 18 0 18 0.47 0 18 0.02 0 18 0.51 2 16 0.48 0 18 0.42 1 17 0.03 2 18 0.56
G2 24 2 22 0 24 2 22 0 24 0 24 1 23 3 22
G3 22 1 21 1 21 0 22 2 20 0 22 2 20 4 22
Histological subtype
Solid 14 1 13 0.007 0 14 0.02 0 14 0.20 1 13 0.08 0 14 0.77 1 13 0.009 3 11 0.06
Acinar 22 2 21 0 22 1 21 2 20 0 22 2 20 4 18
Papillary 15 0 15 1 15 1 14 1 14 0 15 1 14 2 13
Bronchioloalveolar 13 0 13 0 13 0 13 0 13 0 13 0 13 0 13
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(Fig. 5a and b). Although the Kaplan–Meier disease-free interval
curve for ALDH shows a trend for a better patient disease
outcome in patients with lower ALDH mRNA signals, this did not
reach a signiﬁcant level (Fig. 5c).
DISCUSSION
In the present study, we determined the pattern and expression
levels of CSC-associated biomarkers: OCT4A, CD133, ABCG2,
Figure 3: Frequency of mRNA levels of relevant CSC-associated genes based on the pTNM staging. ALDH correlation to stage (a) nodal status (b) and tumour
grade (c); association of CD133 with stage (d) and tumour differentiation (e); and OCT4A correlation to tumour size (f ) and lymph node metastasis (g).
Figure 4: Correlation of CD133, OCT4A and ALDH expression in LAC tumour biopsies. (a) A signiﬁcant association between CD133 and OCT4A (Spearman r = 0.4,
P = 0.002). No correlation was observed between ALDH and OCT4A (b), and between ALDH and CD133 (c).
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SOX2, BMI-1, uPAR and ALDH in paired tumour and non-
tumour LAC biopsies. Further, we assessed their associations
with the different clinicopathological parameters, which may
serve as a basis for use as prognostic indicators in the neoplasm.
Our results illustrated signiﬁcantly increased transcript levels of
OCT4A, SOX2, CD133, BMI-1 and uPAR in tumour tissues com-
pared with those in the corresponding non-tumour biospsies. In
contrast, ABCG2 and ALDH were signiﬁcantly reduced in the
tumour relative to those in the corresponding normal biopsies.
Correlation data afﬁrmed that only OCT4A, CD133 and ALDH
exert signiﬁcant inﬂuence on the clinicopathological parameters
and disease-free intervals of LAC patients. Additionally, we
observed a strong interdependency in the expression between
OCT4A and CD133.
Current studies have reported a strong presence of gene ex-
pression, positivity in immunostaining or protein serum levels of
OCT4A, SOX2, CD133, uPAR, ALDH, ABCG2 and BMI-1, in LAC
tumour specimens [4, 9, 12, 13]. Data emerging from our study
indicate not only the presence of these markers in tumours but,
importantly, higher expression proﬁles of OCT4A, CD133, BMI-1,
SOX2 and uPAR in the tumours compared with their matched
normal tissue counterparts. Up-regulation of these
CSC-associated biomarkers strongly suggest the existence of
CSCs in LAC. Although not yet evident, one current belief of
lung tumorigenesis proposes that CSCs originate from the trans-
formation of lung progenitor cells or lung epithelial cells by
mutagens. Once mutated, these CSCs obtain limitless capacity
for proliferation through dysregulated self-renewal. Given this
premise, it is plausible that lung CSCs may still reﬂect the hall-
marks and phenotypes of normal stem cells [1]. Our data,
showing the increased expression levels of the above-mentioned
CSC markers in the tumour tissues relative to the normal coun-
terparts, strongly supports this model of carcinogenesis.
Contrary to the above, we found that levels of ALDH and
ABCG2 were signiﬁcantly lowered in the paired malignant tissues
relative to their normal counterparts. Being a transporter of
certain chemotherapeutic drugs, most of the studies on ABCG2
expression proﬁles have been associated with drug response and
general disease outcome. The presence of ABCG2 in NSCLC has
also been considered as a predictor of lower drug response, and
shorter progression-free and overall survival [14]. In this study,
the expression proﬁle of ABCG2 in the LAC tumour was found to
have no signiﬁcant relevance to any of the clinicopathological
factors evaluated; hence, we could not assign any pertinent role
to this marker in the oncogenesis of LAC.
ALDH activity is a prevailing stem cell and CSC marker in both
normal and malignant tissues, respectively. However, there are
limited data on the comparison of expression of ALDH in
cancers and their corresponding normal tissues. In the lung,
most of the studies have been focused on the assessment of the
presence or absence of ALDH in the tumour tissues. To the best
of our knowledge, this is the ﬁrst work to explore the differential
expression of ALDH between matched normal and tumour biop-
sies. Patel et al. [15] have recently demonstrated reduced ALDH
expression in pneumocytes derived from normal lungs of non-
smokers compared with elevated levels in those derived from
smokers. This group reasoned that chronic exposure to tobacco
smoke may have induced the increased levels of ALDH as a cel-
lular protective mechanism against this insult. We indeed
observed a signiﬁcantly lower ALDH expression proﬁle in the
normal tissues of non-smokers compared with the smoker
group. However, in the absence of the smoking cohort, a com-
parison of tumour and paired normal tissues illustrates the
expected up-regulation of ALDH in tumour tissues of LAC. The
question of whether ALDH has a protective or oncogenic role in
LAC remains to be answered.
We examined the correlation of CSC-associated gene expres-
sion in the tumour samples, with patient characteristics, tumour
pathology and disease-free interval, and demonstrated direct
associations of CD133, OCT4A and ALDH to the above
Table 2: Cox proportional hazards regression for
disease-free interval
Patients No. (%) Hazard
ratio
95% Cl P-value
OCTA expression
Low 31 3.81 1.02–14.3 0.047
High 30
CD133 expression
Low 31 3.93 1.12–13.8 0.033
High 32
ALDH expression
Low 30 3.30 0.91–11.9 0.068
High 30
Figure 5: The disease-free interval curves based on (a) OCT4A, (b) CD133 and (c) ALDH cut-off values. Patients with high OCT4A and CD133 levels (above cut-off
values) showed signiﬁcantly (OCT4A, P = 0.047; CD133, P = 0.033) low disease-free intervals. Patients with increased ALDH show the same trend but did not reach
a statistical signiﬁcant (ALDH, P = 0.068). Kaplan–Meier survival analysis was used to create the disease-free interval curve.
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parameters. Our data indicated a signiﬁcant relationship
between ALDH and tumour stage and tumour grade in LAC. In
both parameters, we observed signiﬁcantly increased levels of
ALDH in stage I and G1 with a declining trend towards the pro-
gression of the tumour. One of the hallmarks of CSCs is the cap-
acity to undergo asymmetrical division resulting in multi-lineage
differentiation giving rise to phenotypically diverse tumour phe-
notypes. The majority of the studies focusing on ALDH in the ma-
lignant setting have shown that ALDH+ cells are more tumorigenic
in vitro and in vivo, clonogenic, and are able to produce genera-
tions of ALDH+ and ALDH− cells [8, 16], thereby highlighting the
CSC status of ALDH+ cells in neoplastic tissues. Considering the
above, we propose that the increased ALDH expression during
the early stages and in poorly differentiated LAC tumours may be
due to a capacity for aberrant self-renewal, a CSC hallmark, thus
implicating ALDH+ cells in the tumour initiation of LAC. Further,
the reduced levels of ALDH in the later stages of LAC could be
justiﬁed by the fact that ALDH-expressing cells undergo asymmet-
ric division, generating a diverse phenotype and therefore result-
ing in reduced ALDH positivity.
ALDH activity is associated with poor prognosis in leukaemia,
melanoma and breast, bladder, prostrate, human epithelial
cancer patients [2]. A reduced patient survival has been corre-
lated to ALDH positivity in stage I NSCLC and in NSCLC patients
[8, 16]. Consistent with these ﬁndings, we observed a trend for
poor prognosis for patients with high ALDH transcripts, but a
signiﬁcant association with a disease-free interval could not be
depicted. These results, in part, may be attributed to a short
follow-up period of 29 months. Hence, these ﬁndings would
require further prospective validation of ALDH activity with
respect to patient prognosis.
Our results provide evidence of a signiﬁcant association of
CD133 with both tumour stage and differentiation in LAC. The
enhanced CD133 levels in the initial phases of tumour stage and
grade of differentiation together with an observed reduction in
both the later stages of these parameters highly indicate an in-
volvement of CD133 in the tumour initiation of LAC. Evidence
for a key role of CD133 in tumour initiation has been shown in
several other malignancies. Singh and Dirks [17] ﬁrst reported
that CD133+ cells from brain tumours showed self-renewal and
differentiation and were able to recapitulate brain tumour for-
mation in vivo. Since then, inoculation of tumour-derived
CD133+ cells into immune-deﬁcient mice has demonstrated the
capacity to re-form the original tumour in human brain, pan-
creas, colon and liver carcinomas [6]. Together with our results,
these studies provide evidence in support of CD133 as a speciﬁc
surface molecule of CSCs in solid tumours, suggesting that
CD133 is likely to become an effective target of anti-tumour
therapy. With respect to patient prognosis, our results show that
tumours with high levels of CD133 transcripts are associated with
shorter disease-free intervals in comparison with those expressing
low CD133. The role of CD133 as a prognostic marker in lung
cancer has not yet been fully elucidated [11, 18–20]. Woo et al.
[20] and Xu et al. [18] noted an association between CD133 and
poor patient prognosis, while others found no relationship
between the clinicopathological parameters or patient prognosis
[11, 19]. Our results ﬁt in with the studies of the former groups, in
which a high CD133 level correlates with diminished disease-free
intervals, contributing to a poor disease outcome.
Our group has previously reported an aberrant up-regulation
of embryonic transcription factor, OCT4A, in LAC tumour tissue
biopsies [21]. In this study, we found a signiﬁcant association of
OCT4A to both tumour size and lymph node metastasis. OCT4A
ampliﬁcation was markedly higher in tumours <3 cm in compari-
son with larger tumours (>3 cm). In patients without lymph node
metastasis (N0), OCT4A mRNA levels were high but signiﬁcantly
reduced in the tumours with evidence of lymph node metastasis
(N+). Collectively, these ﬁndings point to an involvement of
OCT4A during the initiation phase of LAC. Self-renewal and
pluripotency are central features in tumour initiation and OCT4A
is a key regulator in these processes [4]. In support of our
studies, OCT4A expression has also been implicated in the
tumorigenesis of breast cancer [22]. Additionally, we found that
high OCT4A expression was signiﬁcantly associated with a
shorter disease-free interval. This is in congruence with two
studies showing unfavourable prognosis and poor survival of LAC
patients [4, 23].
Notably, we found a signiﬁcant correlation between OCT4A
and CD133, suggesting an interplay of these two biomarkers in
some regulatory mechanisms in the tumorigenesis of LAC.
Supporting these ﬁndings, Chen et al. [24] reported that knock-
ing down of OCT4A expression blocks the ability of lung
cancer-CD133 + cells to form spheres, colonies and tumours. As
these are properties of CSCs, it is conceivable that OCT4 may
have a basic regulatory role in the expression and behaviour of
CD133 in LAC. This interesting regulatory mechanism warrants
further analysis.
Our study highlights new insights into the cancer biology of
LAC. We found an increased expression of OCT4A, CD133,
BMI-1, SOX2 and uPAR in the tumour samples relative to their
normal counterparts in LAC. It is important to note, however,
that although we assessed the expression of CSC markers in
the tumour as well as normal tissues of each patient, we
cannot completely rule out the effects of other inﬂuencing
factors such as inﬂammation [25]. A current review has sum-
marized that inﬂammation may be involved in several stages of
carcinogenesis, from tumour initiation to tumour promotion
and even in metastatic progression. Particularly in lung cancer,
high serum levels of inﬂammatory cytokines IL-6 and IL-8 have
been associated with increased risk of this neoplasm (reviewed
in [25]). Of the seven CSC markers investigated, only OCT4,
CD133 and ALDH have signiﬁcant associations in the early
phases of tumour stage, differentiation and nodal metastasis.
Our data strongly supports their identity as CSC markers in the
lung, implication in the initiation of tumorigenesis and a nega-
tive prognostic effect in disease survival of LAC. We conclude
that OCT4A, CD133 and ALDH can be used as biomarkers in
the early stage of LAC and as a prognostic tool to predict the
general disease outcome, thus facilitating better therapeutic
strategies.
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APPENDIX. CONFERENCE DISCUSSION
Dr A. Zuin (Padua, Italy): The authors examined a very interesting and intri-
guing ﬁeld of the prognostic impact of cancer stem cells in lung adenocarcin-
oma. I have two questions for you. You talk about disease-free survival in
your paper, but did you correlate the expression of these biomarkers, these
features, with long-term survival? This is the ﬁrst question. Second, what
could be the possible clinical implications of the expression of these biologic-
al features?
Dr Galetta: We began this study together with the University of Berne
about two and a half years ago. To answer your ﬁrst question, the time for
the follow-up is very, very short to reach any signiﬁcance in the evaluation in
regards to long-term survival. We think that in the near future we will be able
with mature results to answer your interesting question on the correlation
between these biological markers and survival in these patients with lung
adenocarcinoma.
With regard to your second question, regarding the clinical implication of
these factors, as I showed in my presentation, we noticed that they were cor-
related in a signiﬁcant way with the tumour size, the T, and the N factors. So
we think that these main factors will be predictive of survival, recurrence and
so on.
Dr G. Friedel (Gerlingen, Germany): I have one question. Have you mea-
sured these stem cell markers also in patients without lung cancer?
Dr Galetta: No, only in patients with lung cancer, adenocarcinoma specif-
ically. The study was conducted with two different kinds of tissue, on lung
adenocarcinoma and on normal lung tissue of the same patients.
Dr K. Nowak (Mannheim, Germany): If you were measuring stem cell
markers in lung cancer, did you perform it on several biopsies in each
tumour. The variation in the expression of stem cell markers in lung cancer
might vary a lot between the vital tumour rim and the centre of the tumour.
This has been shown in a lot of experimental studies.
Dr Galetta: No. Usually I myself performed the biopsies of the lung
tumours, and I usually performed the same kind of biopsy, a little piece of
tumour from the central part to the periphery of the nodule. We didn’t
perform an accurate analysis between the central part expressions or the per-
ipheral part, because most of these cases were initial tumours, T1, so we
didn’t have much tissue. The pathologist requires a lot of tissue to perform
other studies.
Dr Nowak: You have shown in stage III cancers that you had signiﬁcantly
lower expressions of CD133. What percentage of the patients had neoadju-
vant therapy?
Dr Galetta: What group of patients?
Dr Nowak: The advanced cancer group had lower expression proﬁles for
CD133.
Dr Galetta: Yes. It’s about a quarter of patients.
Dr Nowak: And it’s possible that after neoadjuvant therapy, these markers
be affected.
Dr Galetta: We didn’t evaluate the difference between the neoadjuvant
and the adjuvant patients.
Dr R. Milton (Leeds, UK): It was a great deal of work that you presented in
a few slides really. I’m quite excited at the prospect that there was a correl-
ation between the expression of some of those markers and the pathological
staging, presumably based on the tumour and the nodal involvement. Can
you detect any of these markers in the blood?
Dr Galetta: To-date, we didn’t perform this evaluation in this study, but I
think in the future we will be able to have sufﬁcient kits to perform this evalu-
ation also. I think that in the future this will be possible.
Dr Milton: Presumably that potentially would indicate those who may have
metastatic disease.
Dr Galetta: Yes.
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